Articles

Latest KFF Health News Stories

KHN’s ‘What the Health?’: Here Comes Reconciliation

KFF Health News Original

Democrats in Congress reached a tentative agreement to press ahead on a partisan bill that would dramatically expand health benefits for people on Medicare, those who buy their own insurance and individuals who have been shut out of coverage in states that didn’t expand Medicaid. Meanwhile, controversy continues to rage over whether vaccinated Americans will need a booster to protect against covid-19 variants, and who will pay for a new drug to treat Alzheimer’s disease. Rachel Cohrs of Stat and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews KHN’s Rae Ellen Bichell, who reported and wrote the latest KHN-NPR “Bill of the Month” episode about a mother and daughter who fought an enormous emergency room bill.

Red State, Blue State, Twin Outbreak: Behind Wyoming and Colorado’s Anomalous Covid Spikes

KFF Health News Original

Statistics show that Colorado residents are much more likely than Wyoming residents to be vaccinated against covid. Yet both Wyoming and Colorado were among the top 12 states with the highest covid case rates at the beginning of July. A closer look at a pair of similarly sized counties in those states helps explain why.

As Congress Wrestles With Plans to Expand Medicare, Becerra Says Any One Will Do

KFF Health News Original

In an interview for KHN’s “What the Health?” podcast, HHS Secretary Xavier Becerra says the administration is eager for Congress to make changes to Medicare that will provide more benefits and make more older adults eligible for the program. He also said a priority will be making permanent the enhanced premium subsidies for Affordable Care Act marketplace plans.

Drugmakers’ Spending on Stock, Dividends and Executive Pay Exceeds Research, Democrats Say

KFF Health News Original

The pharmaceutical industry argues that large profits are needed to fund extensive research and innovation. But Democrats on the House Oversight and Reform Committee, seeking to bolster their effort to let Medicare negotiate drug prices, say major drug companies plow more of their billions in earnings back into propping up their stock and enriching executives and shareholders.